新药进医保，乳腺癌精准治疗“可及时代”开启

Core Insights - The latest national medical insurance drug list will be implemented starting January 1, 2026, adding 114 new drugs, including 50 global innovative drugs, marking a record high in both proportion and quantity [1] - The inclusion of innovative drugs, particularly in the field of cancer treatment, is expected to significantly improve patient access to previously unaffordable medications [1][4] Group 1: Drug Inclusion and Impact - The updated medical insurance list includes a significant number of innovative drugs, especially for breast cancer treatment, which is the most common malignant tumor among women globally [1] - In 2022, over 350,000 new breast cancer cases were reported in China, resulting in approximately 75,000 deaths, highlighting the critical need for effective treatments [1] - The most common molecular subtype of breast cancer, HR+/HER2-, accounts for about 80% of all breast cancer patients [1] Group 2: Treatment Advancements - Advances in screening and treatment have led to a significant improvement in the prognosis of early-stage HR+/HER2- breast cancer, with a five-year survival rate exceeding 90% [3] - Despite treatment advancements, some patients still face disease progression or drug resistance, with about 57% of late-stage HR+/HER2- breast cancer patients in China carrying specific genetic alterations [3] Group 3: Targeted Therapies - The inclusion of targeted therapies in the updated insurance list addresses the clinical treatment gap for late-stage HR+/HER2- breast cancer patients with PIK3CA, AKT1, or PTEN mutations [3] - Notable drugs like Abemaciclib and Ribociclib have expanded their insurance coverage to include all indications for early breast cancer, effective from January 1, 2026 [3][4] Group 4: Shift in Treatment Paradigm - The entry of targeted drugs into the insurance framework signifies a shift from traditional chemotherapy to more precise, individualized treatment approaches for breast cancer [4] - The price reduction for these new drugs can exceed 90%, making previously unaffordable targeted therapies accessible to patients [4]